Fig. 6: Low doses of simvastatin result in significantly improved survival in an orthotopic MBs xenograft model.

A ICb-1299 human primary cells were injected into the cerebellum of newborn NOD-SCID mice, and mice were divided into control (n = 6) and simvastatin (n = 4). At 20 days old, 40 mg/Kg/day simvastatin was injected i.p in the morning every day in the simvastatin group. B The survival of the mice is plotted over time (log-rank test) (**) P < 0.001. C Histology of the MBs tumours treated or not with 40 mg/kg/day simvastatin. Representative photographs of H&E showing typical MBs tumour morphology at 10 weeks. Staining with human vimentin confirms their origin. Representative bright-field images are shown for Ki-67 and cleaved caspase-3. Quantification is shown as the mean of positive cells per high-power field. Bar, 50 µm. D Histology of the spinal cord of the mouse treated or not with 40 mg/kg/day simvastatin. Representative photographs of H&E showing typical morphology at endpoint experiment. Staining with human vimentin confirms their origin. Bar, 50 µm. E Quantification of the tumour load. (**) P < 0.001; (***) P < 0.0001. H&E: haematoxylin and eosin.